A director at UBS Group AG sold 12,000 shares at 32.468CHF and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
AMG Schedule for Fourth Quarter and Full Year 2025 Earnings Release Amsterdam, 18 February 2026 --- AMG Critical Materials N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") will release its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, at approximately 18:00 CET. AMG will host a conference call to discuss its financial results for the fourth quarter of 2025 at 15:00 CET (14:00 GMT / 9:00AM EST) on Thursday, February 26, 2026. Please connect approximately 10 minutes prior to the beginning of the call to ensure participation. The call-in information is as follows...
Melexis: update on the share buy-back program Press release - Regulated Information Ieper, Belgium – 16 February 2026, 17.45 hrs CET Melexis reports the purchase of 22,000 Melexis shares on Euronext Brussels in the period from 9 February 2026 to 13 February 2026, related to the share buy-back program announced on 10 December 2025. Trade dateTotal shares purchasedAverage price (€)Min price (€)Max price (€)Buyback amount (€)9/2/20264,00055.3053.5055.90221,21510/2/20264,50056.9355.3557.50256,16711/2/20264,50056.3755.6556.85253,64712/2/20264,50056.1655.6557.35252,72713/2/20264,50055.9855.50...
Melexis: update over het aandeleninkoopprogramma Persbericht - Gereglementeerde informatie Ieper, België – 16 februari 2026, 17.45 uur CET Melexis meldt de aankoop van 22.000 Melexis-aandelen op Euronext Brussel in de periode van 9 februari 2026 tot 13 februari 2026, in het kader van het inkoopprogramma aangekondigd op 10 december 2025. InkoopdatumAantal verworven aandelenGemiddelde prijs (€)Laagste prijs (€)Hoogste prijs (€)Aankoop bedrag (€)9/2/20264.00055,3053,5055,90221.21510/2/20264.50056,9355,3557,50256.16711/2/20264.50056,3755,6556,85253.64712/2/20264.50056,1655,6557,35252.72713/...
We raise our target price from €35 to €45 per share, driven by the recent recovery in lithium prices, which has the potential to turn a transition year for AMG into a more exciting one. We maintain our BUY recommendation, with AMG's valuation still undemanding, in light of the re-emergence of the critical materials theme and with key peers trading at substantial premia relative to AMG.
A director at Novartis AG sold 7,500 shares at 156.208USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Melexis: update on the share buy-back program Press release - Regulated Information Ieper, Belgium – 9 February 2026, 17.45 hrs CET Melexis reports the purchase of 10,000 Melexis shares on Euronext Brussels in the period from 2 February 2026 to 6 February 2026, related to the share buy-back program announced on 10 December 2025. Trade dateTotal shares purchasedAverage price (€)Min price (€)Max price (€)Buyback amount (€)2/2/2026-----2/2/2026-----2/2/2026-----2/2/20265,00053.8052.2056.55268,9952/2/20265,00053.1352.5053.45265,662TOTAL10,00053.4752.2056.55534,657 Under the current share bu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.